CMS Coverage and Analysis Group director Louis Jacques tried to temper the widespread enthusiasm for scientific advances in cancer diagnosis in his concluding speech at an Oct. 29 Washington, D.C. symposium on cancer diagnostics and personalized medicine.
He reminded the diagnostics industry that molecular diagnostics for the disease remain a largely unproven technology. “Why are insurers so reluctant to get enthusiastic and really embrace molecular diagnostics